Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. It specializes in seed, early-stage, and growth capital investments primarily within the healthcare sector, with a particular emphasis on biopharma, diagnostics, life sciences, agrifood technology, and technology sectors. The firm is recognized for its strategic approach, providing long-term investment capital to innovative companies that are developing transformative technologies and therapies aimed at improving human health. As a subsidiary of Alexandria Real Estate Equities, Alexandria Venture Investments leverages its deep industry expertise, extensive relationships with investors, and a world-class scientific advisory network to support and fund promising startups and growth-oriented companies in disruptive life science and technology.

SOSV, established in 1995 and headquartered in Princeton, New Jersey, is a global venture capital firm specializing in early-stage investments. It focuses on deep tech innovations in the health and environmental sectors, supporting founders with breakthrough technologies through its HAX and IndieBio startup development programs. SOSV provides resources, facilities, and lab equipment to accelerate product development and scale, with a track record of helping its portfolio companies secure subsequent funding rounds led by top-tier investors.

The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.

OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.

ARCH Venture Partners, established in 1986, is a U.S.-based venture capital firm with a global scope. It specializes in investing in technology companies, with a primary focus on life sciences. ARCH invests conservatively in seed rounds to mitigate risk, and then leads or co-leads subsequent financing rounds until liquidity. The firm is known for its success in commercializing technologies from academic research institutions and national laboratories, often investing in companies co-founded by scientists and entrepreneurs. ARCH has raised over $3 billion across ten funds and has invested in over 150 companies, typically committing between $50,000 and $150 million per company. It seeks a seat on the Board of Directors and maintains a presence in underserved geographic markets. ARCH's investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

Sofinnova Partners, established in 1972 and headquartered in Paris, is a leading venture capital firm focused on the life sciences sector. It manages over €2 billion, investing from seed to later-stage in biopharmaceuticals, medical devices, and industrial biotechnology. The firm proactively sources deals, often leading financings and actively supporting portfolio companies until exit. Sofinnova Partners invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations, playing a significant role in developing transformative innovations that can positively impact the future.

Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.

Perceptive Advisors, established in 1999, is a New York-based investment management firm specializing in the life sciences sector. It invests in both private and public biotechnology, pharmaceutical, medical device, diagnostics, and health services companies across their lifecycle, from seed and early-stage ventures to public equities. The firm employs a long/short equity strategy and conducts in-house research to identify promising opportunities. Perceptive Advisors also offers customized debt financing solutions through its Perceptive Credit Opportunities Fund.

RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.

Google.org is a philanthropic arm of Google, a multinational technology company. It funds and supports nonprofits globally, providing them with funding, tools, and volunteers. Google.org has committed approximately $100 million annually to these efforts, aiming to extend the reach of innovative nonprofits and create lasting global impact.

IndieBio, established in 2014, is a San Francisco-based accelerator firm specializing in Synthetic Biology. It runs intensive four-month programs for early-stage companies and teams with innovative biological concepts. IndieBio invests in seed and early-stage startups globally, focusing on those that use biology as their core technology to solve real-world problems. The firm typically invests $250k, with an initial cash investment of $50k in exchange for an 8% equity stake. It prefers teams with at least two co-founders. IndieBio was the world's first accelerator dedicated to biology-based startups, aiming to address global challenges through innovative biotechnology.

Khosla Impact, established in 2013, is an impact investment firm based in Menlo Park, California. It focuses on assisting high-impact entrepreneurs who develop products and services for the three billion people at the bottom of the world's economic pyramid. The firm invests in for-profit enterprises serving low-income individuals and small businesses in emerging markets, with a primary focus on South Asia. Khosla Impact encourages experimentation and supports entrepreneurs passionate about solving socio-economic challenges through technology and innovative business models.

Novo Holdings, established in 1999, is a Danish asset management firm based in Copenhagen. It serves as the investment arm of the Novo Nordisk Foundation, managing its assets and wealth. The company's primary focus is the life science sector, with a diversified portfolio comprising equities, bonds, real estate, infrastructure, and private investments. Novo Holdings maintains a significant influence on Novo Nordisk A/S and Novozymes A/S, ensuring these companies align with the Novo Group's visions and values. It also invests in early and growth-stage life science companies through its venture capital arm, Novo Ventures, which targets investments ranging from USD 5 million to USD 30 million.

Casdin Capital is a New York-based investment firm established in 2012, specializing in fundamental research within the life sciences and healthcare sectors. The firm focuses on a range of investments, from early-stage to late-stage private opportunities, and is particularly interested in areas such as oncology, digital health, and agtech. As a Registered Investment Adviser, Casdin Capital employs a long-short equity strategy to manage its portfolio. Founded by Eli Casdin, the firm has built a reputation for its analytical approach to investing in innovative healthcare solutions, aiming to capitalize on advancements in the industry. As of October 2020, Casdin Capital managed approximately $2.2 billion in assets.

Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing evolving patient needs worldwide. It operates through several divisions: Novartis Pharmaceuticals for innovative medicines, Sandoz for generics and biosimilars, and Alcon for eye care devices. The company focuses on key therapeutic areas such as oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic diseases. Novartis also invests in early-stage life sciences and biotechnology companies through its venture capital arm, Novartis Venture Fund, seeking innovative therapeutics, medical devices, diagnostics, and drug delivery systems. Additionally, Novartis Animal Health develops products for pets, farm animals, and farmed fish, contributing to animal health and welfare. The company's research and development efforts are supported by the Genomics Institute of the Novartis Research Foundation, which bridges basic science and preclinical drug discovery.

Eli Lilly and Company is a global pharmaceutical corporation that specializes in the discovery, development, manufacturing, and distribution of medicines. Its portfolio spans various therapeutic areas, including neuroscience, cardiometabolic, cancer, and immunology. Notable products include Verzenio for cancer, Mounjaro and Jardiance for cardiometabolic conditions, and Taltz for immunology. The company operates through owned or leased facilities in over 25 countries, selling its products in approximately 135 countries worldwide. Additionally, Eli Lilly and Company Foundation, established in 1968, supports initiatives aimed at improving patient outcomes, enhancing quality of life, and promoting education, particularly in underserved communities.

Innovate UK is a non-departmental public body established in 2007 and based in Swindon, United Kingdom. Funded by a government grant, it supports innovation in science and technology by providing funding services to businesses across various sectors and regions. The organization aims to drive productivity and economic growth by facilitating advancements that contribute to the UK’s economic landscape. In addition to funding, Innovate UK offers a range of services and information related to business and economic development, thereby fostering a supportive environment for innovation.

The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.

Polaris Partners, established in 1996 and headquartered in Boston, Massachusetts, is a venture capital firm focusing on healthcare, life sciences, and biotechnology sectors. The firm invests across various stages, from early-stage companies to growth equity, partnering with repeat entrepreneurs and innovators. Polaris' healthcare portfolio spans digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics, while its life sciences and biotechnology investments center around molecules, platforms, therapeutics, and genomics. With offices in Boston and San Francisco, Polaris has a 20-year history of supporting companies that improve people's lives and work.

T. Rowe Price Group, Inc., established in 1937 and headquartered in Baltimore, Maryland, is a global investment management firm. It serves a diverse range of clients, including individuals, institutional investors, retirement plans, and financial intermediaries. The company offers a broad spectrum of investment strategies, focusing on equity and fixed income markets worldwide. T. Rowe Price employs a fundamental, bottom-up approach, combining in-house and external research, and considers environmental, social, and governance factors in its investment decisions. With offices across North America, Europe, Asia, and Australia, the firm is committed to delivering long-term investment excellence.

Foresite Capital, established in 2011, is a San Francisco-based healthcare and life sciences investment firm with approximately $2 billion under management. It takes a data-driven, collaborative approach to investing, providing not just capital but also a multidisciplinary team of experts to support its portfolio companies. Foresite focuses on growth equity investments across the U.S. healthcare sector, with a particular interest in startups that leverage biology, big data, and technology to improve healthcare outcomes. Its portfolio includes companies like 10x Genomics, Relay Therapeutics, and Element Biosciences. The firm aims to address areas of great unmet clinical need and supports promising healthcare and life sciences businesses at all stages of their development.

Atlas Venture, established in 1980, is a Cambridge, Massachusetts-based venture capital firm with a global presence. It manages over $2 billion in committed capital across multiple funds. The firm specializes in early-stage investing, focusing on life sciences and technology sectors. Atlas Venture creates and invests in biotech startups led by promising entrepreneurs, aiming to build scalable businesses and realize value. It typically invests $500,000 to $5 million in seed and early-stage rounds, with follow-on financing potentially reaching $10 to $20 million per company. Since 1995, Atlas Venture has been involved with over 350 companies, with 50 acquisitions and 40 IPOs.

Janus Henderson Investors is a global asset management firm headquartered in London, United Kingdom, with a history dating back to 1934. The company specializes in delivering investment performance and services to a diverse clientele, including institutional, retail, and high-net-worth clients. It connects these clients with investment professionals who have expertise across a wide range of asset classes, such as equities, fixed income, real estate, and alternative investments. Janus Henderson Investors aims to provide tailored investment solutions that meet the unique needs of its clients while fostering long-term financial growth.

Versant Ventures, established in 1999, is a global healthcare investment firm headquartered in San Francisco, California. With over $2.3 billion under management and offices in North America and Europe, the firm invests across the healthcare sector, with a focus on discovering and developing novel therapeutics. Versant's team, comprising deep investment, operating, and scientific expertise, takes a hands-on approach to company building. Since inception, over 65 Versant companies have achieved successful acquisitions or IPOs.

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Northpond Ventures is a venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. Founded in 2018, the firm specializes in growth capital investments across various sectors, including life sciences, biotechnology, diagnostics, digital health, and emerging technologies. Northpond Ventures aims to support innovative companies that are poised to make significant advancements in healthcare and technology, with a focus on building a better future through its strategic investments. As a Registered Investment Adviser, the firm is committed to fostering developments in therapeutics, artificial intelligence, machine learning, and medical technology.

Lux Capital, established in 2000, is a New York-based venture capital firm managing over $4 billion in assets. It invests in early-stage and growth companies at the intersection of technology and sciences, focusing on sectors such as biochemistry, material science, electronics, infrastructure, and aerospace. Lux actively supports entrepreneurs, having helped build over 20 companies from scratch, and employs a strategy that enhances portfolio companies' connectivity, insights, and industry leadership.

EcoR1 Capital, LLC is an employee-owned investment advisory firm based in San Francisco, California, founded in 2012. Specializing in the biotechnology sector, EcoR1 Capital focuses on identifying and evaluating innovative therapeutic solutions that can significantly enhance patient outcomes. The firm employs a long/short investment strategy primarily within the public equity markets of the United States, while also managing separate client-focused equity and fixed income portfolios. By investing in biotech companies that offer promising new treatments for untreated diseases, EcoR1 Capital aims to advance medical research and build upon the innovative contributions of its predecessors in the healthcare and life sciences fields.

F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.

New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, headquartered in Menlo Park, California, with additional offices in the U.S., India, and China. NEA specializes in investing in technology and healthcare sectors, with a focus on enterprise, consumer, fintech, life sciences, and digital health companies. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. NEA invests globally, with a significant presence in Asia, including China and India, as well as the United States. The firm typically invests between $0.05 million and $20 million per deal.

Redmile Group, established in 2007, is a private equity firm headquartered in San Francisco with an additional office in New York. The company specializes in healthcare investments, focusing on venture capital opportunities within the sector.

The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

Cormorant Asset Management, established in 2013 and headquartered in Boston, Massachusetts, is an employee-owned hedge fund sponsor. It offers services to pooled investment vehicles, specializing in investments across both public and private markets within the biotechnology and life sciences sectors.

Deerfield Management, established in 1994 and headquartered in New York, is a healthcare-focused investment management firm. It provides long-term structured investments in both public and private healthcare companies, spanning life science, medical device, diagnostic, digital health, and health service industries. The firm also offers information and investment services to foster a healthcare ecosystem.

Venrock, established in 1969, is a venture capital firm headquartered in Palo Alto, California, with additional offices in New York. It specializes in seed and early-stage investments, primarily in technology and healthcare sectors. The firm partners with entrepreneurs to build successful, enduring companies, with a notable track record including Apple, Athenahealth, and Gilead Sciences. Venrock also manages dedicated funds for healthcare investments, such as Venrock Healthcare Capital Partners, focusing on both private and public biotechnology companies.

Wellington Management Company, founded in 1928 and headquartered in Boston, Massachusetts, is an investment management firm that caters to a diverse range of institutional clients, including high-net-worth individuals, pension plans, endowments, insurers, and government entities. The firm employs a comprehensive approach to investment management that encompasses equity, fixed income, currency, commodity, and alternative markets. Wellington Management offers various services, including asset allocation, multi-manager strategies, and specialized investment approaches. The firm is known for its focus on both growth and value stocks across small-cap, mid-cap, and large-cap companies, and it manages a variety of investment vehicles, such as mutual funds and hedge funds, to meet the unique needs of its clientele.

Fidelity International, established in 1969, is a privately-owned global investment management firm headquartered in Bermuda. It specializes in providing investment solutions and retirement expertise to a diverse range of clients, including institutions, individuals, and their advisers. The company offers a broad spectrum of services, such as stocks and shares, personal pensions, investment accounts, advice services, wealth management, and workplace pension administration. With over $379 billion in total client assets under management, Fidelity International serves approximately 2.4 million clients across Asia Pacific, Europe, the Middle East, and South America. Its mission is to help clients build better futures for themselves and future generations by offering world-class investment solutions and long-term investment strategies.

Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.

Leaps by Bayer is the corporate venture capital arm of Bayer, established in 2015 and headquartered in Leverkusen, Germany. The company focuses on investing in groundbreaking advancements within the life sciences, particularly in biotechnology and agriculture. By targeting disruptive biotechnologies, Leaps by Bayer aims to make significant and lasting contributions that can profoundly impact humanity. Through its strategic investments, the firm seeks to support innovations that address critical challenges in healthcare and food production.

Sanofi Oncology, a division of global healthcare company Sanofi, focuses on developing and delivering innovative treatments for various types of cancer. With a rich heritage in oncology, Sanofi Oncology leverages its extensive knowledge base to research and treat cancer from multiple angles, addressing diverse patient needs and disease stages. The company's portfolio includes therapies for rare diseases, immunology, and cardiovascular conditions, among others. Sanofi's commitment to patients drives its strategy to create long-term value through innovative treatments, from research and development to manufacturing and marketing.

DCVC, established in 2010 and based in Palo Alto, California, is a venture capital firm focusing on early-stage investments in deep tech companies. The firm backs entrepreneurs leveraging advanced technologies to drive transformative change across various sectors, including artificial intelligence, manufacturing, and life sciences. DCVC's portfolio comprises companies that combine cutting-edge science and technology with unique computing and algorithmic advantages, aiming to reduce capital and operational expenses. DCVC Bio, a subsidiary founded in 2018 and based in San Francisco, specializes in investing in early-stage life science companies powered by deep tech approaches, targeting sectors such as therapeutics platforms, agriculture, and industrial biotechnologies. Both DCVC and DCVC Bio are registered investment advisers.

RTW Investments, LP is an employee-owned hedge fund manager based in New York, with additional offices in London and Shanghai. Established in 2009, the firm specializes in investments within the healthcare sector, focusing on life sciences, big data, and digital health. RTW Investments engages in a comprehensive investment strategy that spans the entire lifecycle of healthcare companies, including company creation, early-stage venture capital, alternative financing, and public company investments. The firm conducts thorough in-house fundamental research to inform its investment decisions, managing both pooled investment vehicles and separate client-focused equity and fixed income portfolios.

HSG, formerly known as Sequoia Capital China, is a global venture capital and private equity firm, managing over USD 55 billion across various funds. Established in 2005, HSG invests in technology, healthcare, and consumer sectors, with a focus on seed, venture, growth, buyout, and infrastructure stages. The firm has backed over 1,500 companies, with more than 160 listed on public exchanges and over 140 achieving unicorn status. HSG operates globally, with offices in Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo, and Singapore, providing extensive resources and industry expertise to its portfolio companies.

Kurma Partners, established in 2009, is a Paris-based private equity and venture capital firm specializing in early-stage investments in healthcare and biotechnology sectors across Europe. The company focuses on financing innovation from pre-creation to development capital, supporting therapeutic and medical innovations, and collaborating with leading research institutes and hospitals. Kurma Partners manages several funds, including Kurma Biofund I, II, and Kurma Diagnostics, making it a significant player in European healthcare financing.

The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.

Deep Track Capital is a private equity investment firm established in 2020 and based in Greenwich, Connecticut. It specializes in the life sciences and biotechnology sectors, focusing on forming partnerships with management teams of innovative public and pre-IPO biotechnology companies. The firm aims to leverage its expertise and extensive network to provide value beyond capital, actively participating in transactions and often leading investment rounds while collaborating with other qualified investors. As a Registered Investment Adviser, Deep Track Capital is dedicated to fostering growth and innovation within the life sciences industry.

Surveyor Capital is a fundamental equities business that operates sector-aligned investment teams focusing on market neutral strategies. The company aims to generate alpha by gaining a deep understanding of each company's strategy, management teams, performance drivers, and industry trends over the medium and long term. With a focus on fundamental analysis, Surveyor Capital strives to achieve success through a comprehensive approach to investment in the equities market.

Andreessen Horowitz, established in 2009 by Marc Andreessen and Ben Horowitz, is a prominent venture capital firm based in Menlo Park, California. The company specializes in investing in software businesses, with a focus on sectors such as bio + healthcare, artificial intelligence, consumer, enterprise, fintech, and infrastructure. It typically invests in startups at various stages, from seed to late-stage, with a flexible investment range of $0.025 million to $50 million. The firm is known for its focus on disruptive technology and has raised multiple funds to support its investment strategy.

Section 32, established in 2017, is a California-based investment firm led by Bill Maris, the former CEO of GV (Google Ventures). The company focuses on early-stage investments in life science, healthcare, and technology sectors across the United States. It primarily invests between USD 5 to USD 10 million in 25 to 30 companies per fund, with a goal to accelerate the discovery, development, and distribution of innovative technologies that enhance the human condition. The firm's portfolio spans various tech subsectors, including artificial intelligence, enterprise software, cybersecurity, fintech, quantum computing, computational biology, and biotechnology.